Objective: The aim of this study was to evaluate the efficacy and tolerability of escitalopram in the treatment of seasonal affective disorder (SAD, fall-winter depression).
Methods: Twenty SAD patients were included in an 8-week drug surveillance. Patients were treated with open-label escitalopram at a dosage of 10 to 20 mg per day. Efficacy assessments included the Structured Interview Guide for the Hamilton Depression Rating Scale (SAD version; SIGH-SAD), the Clinical Global Impression (CGI) and the Social Adaptation Self Evaluation Scale (SASS). Side effects were monitored with the UKU Side Effect Rating Scale.
Results: From week 2 onwards, escitalopram significantly reduced SIGH-SAD score and CGI severity score (p<0.001). From week 4 onwards, the SASS score was also significantly improved (p<0.05). The response rate (SIGH-SAD<50% of baseline value) after treatment for 8 weeks was 95%, the rate of remission (SIGH-SAD ≤7) was 85%. Side effects were mild to moderate and did not lead to cessation of therapy.
Conclusion: These results suggest that escitalopram is an efficacious and altogether safe treatment for seasonal depression.
References
-
1 American Psychiatric Association .Diagnostic and Statistical Manual of Mental Disorder. 4th edition, text revision (DSM-IV-TR) Washington, DC: American Psychiatric Press 2000
-
2
Bech P.
Social functioning: should it become an endpoint in trials of antidepressants?.
CNS Drugs.
2005;
19
313-324
-
3
Bech P, Allerup P, Gram LF, Reisby N, Rosenberg R, Jacobsen O. et al .
The Hamilton depression scale. Evaluation of objectivity using logistic models.
Acta Psychiatr Scand.
1981;
63
290-299
-
4
Bech P, Andersen HF, Wade A.
Effective dose of escitalopram in moderate versus severe DSM-IV major depression.
Pharmacopsychiatry.
2006;
39
128-134
-
5
Bosc M, Dubini A, Polin V.
Development and validation of a social functioning scale, the Social Adaptation Self-evaluation Scale.
Eur Neuropsychopharmacol.
1997;
7
((Suppl 1))
57-70
, discussion 71-73
-
6
Brambilla P, Cipriani A, Hotopf M, Barbui C.
Side-effect profile of fluoxetine in comparison with other SSRIs, tricyclic and newer antidepressants: a meta-analysis of clinical trial data.
Pharmacopsychiatry.
2005;
38
69-77
-
7
Bundesgesetzblatt für die Republik Österreich .
, Bundesgesetz vom 2. März 1983 über die Herstellung und das Inverkehrbringen von Arzneimitteln (Arzneimittelgesetz). BGBl. Nr. 185/1983
-
8
Burke WJ, Gergel I, Bose A.
Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients.
J Clin Psychiatry.
2002;
63
331-336
-
9
Chen F, Larsen MB, Sanchez C, Wiborg O.
The S-enantiomer of R,S-citalopram, increases inhibitor binding to the human serotonin transporter by an allosteric mechanism. Comparison with other serotonin transporter inhibitors.
Eur Neuropsychopharmacol.
2005;
15
193-198
-
10
Ferguson JM.
SSRI antidepressant medications: adverse effects and tolerability.
Prim Care Companion J Clin Psychiatry.
2001;
3
22-27
-
11 First MB, Spitzer RL, Gibbon M, Williams JB. Structured clinical interview for DSM-IV axis I disorders - patient edition. SCID-I/P, version 2.0. New York, NY: New York State Psychiatric Institute, Biometric Research Department 1996
-
12
Goodman WK, Bose A, Wang Q.
Treatment of generalized anxiety disorder with escitalopram: pooled results from double-blind, placebo-controlled trials.
J Affect Disord.
2005;
87
161-167
-
13 Guy W. ECDEU assessment manual for psychopharmacology. US Department of Health, Education and Welfare publication (ADM) 76-338. Rockville, MD: National Institute of Mental Health 1976
-
14 Kasper S. Jahreszeit und Befindlichkeit in der Allgemeinbevölkerung.Eine Mehrebenenuntersuchung zur Epidemiologie, Biologie und therapeutischen Beeinflußbarkeit (Lichttherapie) saisonaler Befindlichkeitsschwankungen. Monographien aus dem Gesamtgebiet der Psychiatrie, Bd. 66. Berlin, Heidelberg, New York, Tokyo: Springer 1991
-
15
Kasper S, Rogers LBS, Yancey A, Schulz PM, Skwerer RG, Rosenthal NE.
Phototherapy in individuals with and without subsyndromal seasonal affective disorder.
Arch Gen Psychiatry.
1989;
46
837-844
-
16
Kasper S, Spadone C, Verpillat P, Angst J.
Onset of action of escitalopram compared with other antidepressants: results of a pooled analysis.
Int Clin Psychopharmacol.
2006;
21
105-110
-
17
Kasper S, Stein DJ, Loft H, Nil R.
Escitalopram in the treatment of social anxiety disorder: randomised, placebo-controlled, flexible-dosage study.
Br J Psychiatry.
2005;
186
222-226
-
18
Kennedy SH, Andersen HF, Lam RW.
Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis.
J Psychiatry Neurosci.
2006;
31
122-131
-
19
Klein N, Sacher J, Geiss-Granadia T, Attarbaschi T, Mossaheb N, Lanzenberger R. et al .
Multiple Dose Administration of Escitalopram Resulted in a Higher Serotonin Transporter Occupancy than Citalopram: A [I123]ADAM SPECT Study in Healthy Volunteers.
Biol Psychiatry.
2006;
59
((Suppl 1))
246
-
20
Lam RW, Andersen HF.
The influence of baseline severity on efficacy of escitalopram and citalopram in the treatment of major depressive disorder: an extended analysis.
Pharmacopsychiatry.
2006;
39
180-184
-
21
Lam RW, Gorman CP, Michalon M, Steiner M, Levitt AJ, Corral MR. et al .
Multicenter, placebo-controlled study of fluoxetine in seasonal affective disorder.
Am J Psychiatry.
1995;
152
1765-1770
-
22
Lam RW, Levitt AJ, Levitan RD, Enns MW, Morehouse R, Michalak EE. et al .
The Can-SAD study: a randomized controlled trial of the effectiveness of light therapy and fluoxetine in patients with winter seasonal affective disorder.
Am J Psychiatry.
2006;
163
805-812
-
23
Lepola UM, Loft H, Reines EH.
Escitalopram (10-20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care.
Int Clin Psychopharmacol.
2003;
18
211-217
-
24
Lingjærde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K.
The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patietns.
Acta Psychiatr Scand.
1987;
76
((Suppl 334))
1-100
-
25
Llorca PM, Azorin JM, Despiegel N, Verpillat P.
Efficacy of escitalopram in patients with severe depression: a pooled analysis.
Int J Clin Pract.
2005;
59
268-275
-
26
Moscovitch A, Blashko CA, Eagles JM, Darcourt G, Thompson C, Kasper S. et al .
A placebo-controlled study of sertraline in the treatment of outpatients with seasonal affective disorder.
Psychopharmacolgy (Berl).
2004;
171
390-397
-
27
Neumeister A, Konstantinidis A, Praschak-Rieder N, Willeit M, Hilger E, Stastny J. et al .
Monoaminergic function in the pathogenesis of seasonal affective disorder.
Int J Neuropsychopharmacol.
2001;
4
409-420
-
28
O’Sullivan RL, Fava M, Agustin C, Baer L, Rosenbaum JF.
Sensitivity of the six-item Hamilton Depression Rating Scale.
Acta Psychiatr Scand.
1997;
95
379-384
-
29
Owens MJ, Knight DL, Nemeroff CB.
Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine.
Biol Psychiatry.
2001;
50
345-350
-
30
Partonen T, Lonnqvist J.
Moclobemide and fluoxetine in treatment of seasonal affective disorder.
J Affect Disord.
1996;
41
93-99
-
31
Pjrek E, Winkler D, Kasper S.
Pharmacotherapy of seasonal affective disorder.
CNS Spectr.
2005;
10
664-669
, quiz 672
-
32
Pjrek E, Winkler D, Stastny J, Konstantinidis A, Heiden A, Kasper S.
Bright light therapy in seasonal affective disorder - does it suffice?.
Eur Neuropsychopharmacol.
2004;
14
347-351
-
33 Rosenthal NE, Bradt GH, Wehr TA. Seasonal Pattern Assessment Questionnaire. Washington, DC: National Institute of Mental Health 1987
-
34
Rosenthal NE, Sack DA, Gillin JC, Lewy AJ, Goodwin FK, Davenport Y. et al .
Seasonal affective disorder: a description of the syndrome and preliminary findings with light therapy.
Arch Gen Psychiatry.
1984;
41
72-80
-
35
Ruhrmann S, Kasper S, Hawellek B, Martinez B, Hoflich G, Nickelsen T. et al .
Effects of fluoxetine versus bright light in the treatment of seasonal affective disorder.
Psychol Med.
1998;
28
923-933
-
36
Rush AJ, Bose A.
Escitalopram in clinical practice: results of an open-label trial in a naturalistic setting.
Depress Anxiety.
2005;
21
26-32
-
37
Sanchez C, Bogeso KP, Ebert B, Reines EH, Braestrup C.
Escitalopram versus citalopram: the surprising role of the R-enantiomer.
Psychopharmacology.
2004;
174
163-176
-
38
SPSS Inc .
, SPSS 12.0 for Windows. Release 12.0. Chicago, IL, USA; 1989-2003
-
39
Stahl SM, Gergel I, Li D.
Escitalopram in the treatment of panic disorder: a randomized, double-blind, placebo-controlled trial.
J Clin Psychiatry.
2003;
64
1322-1327
-
40
Wade A, Michael Lemming O, Bang Hedegaard K.
Escitalopram 10 mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care.
Int Clin Psychopharmacol.
2002;
17
95-102
-
41
Weissman MM, Olfson M, Gameroff MJ, Feder A, Fuentes M.
A comparison of three scales for assessing social functioning in primary care.
Am J Psychiatry.
2001;
158
460-466
-
42 Williams JBW, Link MJ, Rosenthal NE, Amira L, Terman M. Structured Interview Guide for the Hamilton Depression Rating Scale - Seasonal Affective Disorder Version, 2002 rev. New York, NY: New York State Psychiatric Institute 2002
-
43
Winkler D, Pjrek E, Iwaki R, Kasper S.
The treatment of seasonal affective disorder.
Expert Rev Neurother.
2006;
6
1039-1048
-
44
Winkler D, Pjrek E, Klein N, Kasper S.
Escitalopram in employed people - Results from an observational study in 2378 patients.
Psychopharmakotherapie.
2006;
13
, in press
-
45
Winkler D, Praschak-Rieder N, Willeit M, Lucht MJ, Hilger E, Konstantinidis A. et al .
Saisonal abhängige Depression (SAD) in zwei deutschsprachigen Universitätszentren: Bonn, Wien. Seasonal affective disorder in two German-speaking university centers: Clinical and demographic characteristics (German).
Nervenarzt.
2002;
73
637-643
Correspondence
E. Pjrek
Department of General Psychiatry
Medical University of Vienna
Währinger Gürtel 18-20
1090 Vienna
Austria
Phone: +43/1/40 400 35 68
Fax: +43/1/40 400 30 99
Email: edda.pjrek@meduniwien.ac.at
